iZafe Group AB (publ), a medical technology company, researches, develops, and markets medical products for medication and drug management in Sweden and internationally. More Details
+ 1 more risk
Overvalued with concerning outlook.
Share Price & News
How has iZafe Group's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: IZAFE B has not had significant price volatility in the past 3 months.
7 Day Return
SE Healthcare Services
1 Year Return
SE Healthcare Services
Return vs Industry: IZAFE B exceeded the Swedish Healthcare Services industry which returned -30.9% over the past year.
Return vs Market: IZAFE B underperformed the Swedish Market which returned 16.9% over the past year.
Price Volatility Vs. Market
How volatile is iZafe Group's share price compared to the market and industry in the last 5 years?
Simply Wall St News
5 months ago | Simply Wall StAnalyst Estimates: Here's What Brokers Think Of iZafe Group AB (publ) (STO:IZAFE B) After Its First-Quarter Report
5 months ago | Simply Wall StRead This Before Selling iZafe Group AB (publ) (STO:IZAFE B) Shares
6 months ago | Simply Wall StWhat Type Of Shareholder Owns iZafe Group AB (publ)'s (STO:IZAFE B)?
Is iZafe Group undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate IZAFE B's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate IZAFE B's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: IZAFE B is unprofitable, so we can't compare its PE Ratio to the XE Healthcare Services industry average.
PE vs Market: IZAFE B is unprofitable, so we can't compare its PE Ratio to the Swedish market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate IZAFE B's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: IZAFE B is good value based on its PB Ratio (4.3x) compared to the SE Healthcare Services industry average (5.2x).
How is iZafe Group forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: IZAFE B is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: IZAFE B is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: IZAFE B is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: IZAFE B's revenue (15.1% per year) is forecast to grow faster than the Swedish market (3.1% per year).
High Growth Revenue: IZAFE B's revenue (15.1% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: IZAFE B is forecast to be unprofitable in 3 years.
How has iZafe Group performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: IZAFE B is currently unprofitable.
Growing Profit Margin: IZAFE B is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: IZAFE B is unprofitable, and losses have increased over the past 5 years at a rate of 42.9% per year.
Accelerating Growth: Unable to compare IZAFE B's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: IZAFE B is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare Services industry (-14.9%).
Return on Equity
High ROE: IZAFE B has a negative Return on Equity (-80.73%), as it is currently unprofitable.
How is iZafe Group's financial position?
Financial Position Analysis
Short Term Liabilities: IZAFE B's short term assets (SEK2.7M) do not cover its short term liabilities (SEK20.5M).
Long Term Liabilities: IZAFE B's short term assets (SEK2.7M) do not cover its long term liabilities (SEK5.3M).
Debt to Equity History and Analysis
Debt Level: IZAFE B's debt to equity ratio (34.5%) is considered satisfactory.
Reducing Debt: IZAFE B's debt to equity ratio has increased from 15% to 34.5% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: IZAFE B has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: IZAFE B has less than a year of cash runway if free cash flow continues to reduce at historical rates of 35.9% each year
What is iZafe Group current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate IZAFE B's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate IZAFE B's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if IZAFE B's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if IZAFE B's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of IZAFE B's dividend in 3 years as they are not forecast to pay a notable one for the Swedish market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Anders Segerstrom (35 yo)
Mr. Anders Segerström serves as the Chief Executive Officer at iZafe Group AB (publ) (formerly known as MediRätt AB (publ)) since 2019. Mr. Segerström has been in leading company roles in the fields of bus ...
|Chief Executive Officer||1.75yrs||no data||no data|
|Co-Founder||no data||no data||no data|
|Chief Operating Officer||3.75yrs||no data||no data|
|COO & Director||1.08yrs||no data||no data|
|Sales Manager & VP||1.75yrs||no data||no data|
Experienced Management: IZAFE B's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.
|COO & Director||1.08yrs||no data||no data|
|Acting Chairman of the Board||1.75yrs||no data||no data|
|Alternate Director||no data||no data||no data|
|Director||6.75yrs||no data||no data|
|Director||2.75yrs||no data||no data|
Experienced Board: IZAFE B's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 69.9%.
iZafe Group AB (publ)'s company bio, employee growth, exchange listings and data sources
- Name: iZafe Group AB (publ)
- Ticker: IZAFE B
- Exchange: OM
- Founded: 2008
- Industry: Health Care Technology
- Sector: Healthcare
- Market Cap: kr115.673m
- Shares outstanding: 32.77m
- Website: https://www.izafe.se
Number of Employees
- iZafe Group AB (publ)
- Stockholmsvägen 33
- Stockholm County
- 181 33
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|IZAFE B||OM (OMX Nordic Exchange Stockholm)||Yes||Class B Shares||SE||SEK||Apr 2011|
|M02||BST (Boerse-Stuttgart)||Yes||Class B Shares||DE||EUR||Apr 2011|
iZafe Group AB (publ), a medical technology company, researches, develops, and markets medical products for medication and drug management in Sweden and internationally. The company offers Dosell, a drug d ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/10/21 21:19|
|End of Day Share Price||2020/10/21 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.